Print Page   |   Sign In   |   Register
Newsletters
Blog Home All Blogs
Search all posts for:   

 

View all (114) posts »
 

Black Swan Connection August 2019

Posted By Administration, Monday, August 19, 2019

August 2019

                

 6,462     1,414       472         8           6


Our goal with the Black Swan Connection is to provide our subscribers, investors and financial professional compatriots outstanding investment insight that is a step above and outside of what will normally be found in mainstream financial press. To that end we have brought together seasoned, successful, and some of the brightest professionals in their respective fields to provide the articles and advice that is based on decades of practice in the field.

Black Swan Connection Newsletter Signup

 

Breaking News

 

Tesla is a story we’ve been covering for a while- No good news here…..

Slumping Tesla Stock Headed Into Test of 2019 Low

Controversial automaker Tesla, Inc. (TSLA) is slumping badly in this tough summer market, dropping like a rock after a six-week oversold rally reversed in July at major resistance between $250 and $270. Adding to growing shareholder anxiety, the stock just broke intermediate support near $230, exposing a second trip into the psychological $200 level and a critical test at June's three-year low at $176.99. First, Wall Street is concerned Tesla doesn't have a viable path to profitability after it reported a much greater-than-expected loss in July's quarterly report.

Read Full Commentary

 

Feature Article

For Microcaps…Its Rough Out There

By: Dave Lavigne

August 2019

I have been providing independent microcap stock research under my own labels since 2002.  Prior to that, I provided the same on the sell side for small regional broker dealers, and that included research as a part of those entities’ corporate finance due diligence. I have been at this a while.

Over those periods that I was preparing research for “public consumption” I kept a track record of  sorts comparing my research universe to that of the performances of three major U.S. equity indices; the Dow Jones Industrial Average, the NASDAQ and the S&P 500. Over much of that period, (and over reasonable periods of time) my research universes typically outperformed those indices, and often by meaningful margins.  As a matter of full disclosure, there are a number of nuances that impact the relevance of those comparisons (transaction costs, spreads, liquidity etc.), so I fully submit, while the stock picks as whole have performed well, I am certainly no guru, and comparing the picks to those indices has some holes. 

Read Complete Article
 

8-2-19 Canbiola, Inc. (OTCQB:CANB)

Canbiola Launches Dedicated Canbiola-Branded CBD Dispensing Machine

Initial 25 Units Will Target Medical Offices

HICKSVILLE, NY, Aug. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate announced today the launch of its own Canbiola-branded CBD product dispensing machine. An initial order for the first 25 units has been placed with the installations expected to occur in August and September.

Read Complete Press Release

 

7-16-19 Antibe Therapeutics, Inc. TSXV:ATE, OTCQB:ATBPF)

Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The Company's audited 2019 consolidated financial statements, MD&A and AIF are available on SEDAR.

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation.

Read Complete Press Release

 

7-11-19 Trickle Research issues update and allocation increase to 7
AzurRx Biopharma, Inc.  NASDAQ AZRX
12-24 Month Price Target $10.25

AZRX made the following announcement the other day regarding a new clinical trial they are preparing. They also hosted a call to discuss the logic behind the trial. Here is that release: AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

  • Dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) in CF patients with severe exocrine pancreatic insufficiency (EPI)
  • .Patients in study have persistent malnutrition and clinical symptoms of fat malabsorption despite being on the maximum daily doses of PERTs.
  • First patient visits have been completed in Hungary.
  • Preliminary data expected in early 2020.

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) --AzurRx BioPharma, Inc. (AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has initiated a Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF) that suffer from severe exocrine pancreatic insufficiency (EPI), but continue to experience clinical symptoms of fat malabsorption despite taking the maximum daily dose of PERTs.

Read Complete Report

 

New Distribution Partner for SMM

In addition to our ongoing growth in distribution we have added a new very important distribution partner in Quote Media.

https://www.quotemedia.com/

They are the premier provider of quote and news services to the financial Industry in North America. They current have some 675 subscribers and publishers of their quote and news feeds including major stock exchanges like NASDAQ and the Toronto Stock Exchange and an extensive list of portfolio managers both in North America and abroad.

All Research updates, releases and news articles will automatically be uploaded from SMM to Quote Media through our RSS feed and will be then ticker tagged and distributed across the Quote Media network in real Time.

This will begin next week and is provided by SMM at no additional charge.

If you have any questions, please feel free to email or give me a call.

 

SMM Coverage-Special Situations

Elio Motors, Inc. (ELIO) $.93 8-15-19

What’s that old song? - slip sliding away……

Petition for class action lawsuit

SHORT- Elio Motors, Inc. –ELIO Nov-2016  $11.80  Dec 17-18 price $3.15 starting to slip slide away again. (nice chance to add to short if you can get a borrow on ELIO).  Last news was almost 5 months ago from company. Still on perpetual begathon for new reservations. Still needs $300 million plus another $545,000 to cover this fine, but reality is that this car cannot be built for the price he talks about.


Nothing new in SEC Filings and no news now for 7 months- That’s NOT good news

Posted by u/snugglesdog

 

 

August-19 MODEL PORTFOLIO FOR TRICKLE RESEARCH, LLC.:

 

Initiation

 

Price

Initiation

Price @

 

Stock

Symbol

Date

Allocation

Target

Cost Px.

8/8/2019

 

SRAX (Social Reality)

SRAX

Multiple

5

$15.00

$1.79

$3.76

 

Pure Cycle

PCYO

5/5/17

3

$12.00

$7.60

$10.74

 

Command Center

CCNI

9/8/17

5

$8.75

$4.44

$7.75

 

Endurance Exploration

EXPL

11/6/17

3

$0.29

$0.18

$0.12

 

Assure Holdings Corp.

ARHH

11/10/17

5

$6.00

$2.90

$1.44

 

AzurRx BioPharma

AZRZ

2/7/18

7

$10.25

$2.96

$0.94

 

Camino Minerals, Corp

CAMZF

4/6/18

6

$0.90

$0.26

$0.09

 

PetroShare Corp

PRHR

5/31/18

5

$2.65

$1.44

$0.06

 

Gold Resource Corp

GORO

7/30/18

5

$7.35

$6.49

$3.60

 

Summit Wirelss

WISA

9/28/18

5

$9.25

$4.30

$0.99

 

Alvoperto Energy, Ltd.

ALVOF

11/7/18

5

$1.10

$0.39

$0.57

 

SG Blocks

SGBX

2/28/19

5

$6.25

$2.84

$6.25

 

H-Source Holdings

HSCHF

4/9/19

4

$0.19

$.06

$0.04

 

Generation Next Brands

VEND

4/10/19

3

$1.10

$.59

$.050

 

 

 

Initiation

 Termination 

 

Price

Initiation

Termination

Terminated Coverage

Symbol

Date

Date

Allocation

Target

Price

Price

ID Watchdog

IDW

10/13/16

8/28/2017

4

$0.42

$0.14

$0.40

GrowGeneration

GRWG

6/20/17

12/21/17

4

$3.40

$2.00

       $3.44  

Barfresh Food Group

BRFH

 

8/20/18

1

 

$0.55

$0.53

Semler Scientific

SMLR

12/27/17

11/7/18

    4

$15.00

$8.00

$31.99

New Jersey Mining

NJMC

4-18

5/16/19

           3

$0.30

$0.12

$1.31

 

 

 

 

 

 

 

 

 

For complete details and assumptions please see the assumptions and explanations document Click Here

For a review and details on 2017 performance and model portfolio assumptions  Click Here

*Please note Dave Lavigne in the principal in Trickle Research and is also the editor of the Black Swan Connection Newsletter and an ongoing contributor to SMM.

 

August 15-19

COMPANY QUOTES, LISTINGS RESEARCH AND NEWS

Company

   

Premium

Research

News

(listing, quotes, news, research)

 

Profile

Updates

Updates

Alvopetro Energy, Ltd. (ALVOF)

 

Profile

  06/20/19

News

Antibe Therapeutics, Inc (ATBPF)

 

 Profile

11/11/18

News

AzuerRx Biopharma, Inc. (AZRX)

 

07/11/19

News

Camino Minerals Corp. (CAMZF)

 

04/06/18

News

Canbiola, Inc. (CANB)

 

Profile

 

News

Clean Coal Technologies, Inc (CCTC)

Profile

 

News

Command Center , Inc. (CCNI)

   

11/13/18

News

Endurance Exploration Group, Ltd (EXPL)

 

 Profile

  03-26/19

News

FULLSHARE HOLDINGS LTD. (607) HK

 

09/07/18

News

Guangdong Land Holdings Limited (124) HK

06-06/19

News

H-Source Holdings, Ltd (HSCHF)

04/09/19         

News

Petroshare Corp. (PRHR)

 

08/23/18

 

Summit Wireless Technologies, Inc.

   

  06/04/19

News

Social Reality, Inc. (SRAX)

   

02/05/19

News

 

 

Go to ValuEngine.com

    
 

August 9th, 2019  by Paul Henneman

ValuEngine Market Valuation update for the week of August 9, 2019. Stock pick of the week is ticker ALNY (Alnylam Pharmaceuticals, Inc.). The models continue to like the markets better than previously in 2019 after the recent pull back with nearly 70% of stocks covered now undervalued. Read on for full updated numbers and stock pick.

www.ValuEngine.com to log in, or free two-week full trial. Over 5,000 stocks, 16 sector groups, 140 plus industries covered every day.

 

VALUATION WATCH: Overvalued stocks now make up 30.78% of our stocks assigned a

valuation and 11.72% of those equities are calculated to be overvalued by 20% or more.

Read Full Report

 

SMM Research Subscription Service.
Black Swan Research

Subscribers will get Real Time notification as Research Reports and updates are available as well as latest press releases and news on the companies covered.

Black Swan Research coverage is a compilation of some of the best independent providers of Micro Cap Research.  The service focuses on micro-cap companies that are typically not followed by Wall Street analysts.  In addition our subscription research service includes ValuEngine research on over 5,000 stocks with stock valuations, Buy/Hold/Sell recommendations, and forecasted target prices.

 Click Here for Complete Description

See Below for current coverage and info regarding our Research providers

Trickle Research Click Here for More info>>

*Research on the following companies is available to BS Research or Trickle research subscribers only

  • Pure Cycle (PCYO)  -

  • Semler Scientific, Inc. (SMLR)

Greenridge Global, LLC Click Here for More Info>>

ValuEngine Click Here for More Info >>

ValuEngine.com (VE) is a stock valuation and forecasting service founded by Ivy League finance academics. VE utilizes the most advanced quantitative techniques and analysis available.

To Subscribe Please click Here
 

Reg A or D 506(c)

If you have a Reg A or 506(c) offering you would like us to distribute to our database, please give us a ring or email to:
727-823-3987
cdilley@smm.global

 


Event Calendar Updates

Summer doldrums- Nothing coming up immediately

The National Investment Banking Association (NIBA) is proud to host its 147th investment conference on November 12-13, 2019 at The Westin New York at Times Square in New York, NY.

Click Here for Details


Carl Dilley
cdilley@smm.global

 

Visit our homepage for up to the minute Financial News, Quotes and our Latest Black Swan Connection Newsletter

Stock Market Manager Homepage

-SMM Distribution Update-

Distribution (Reach)

SMM Global Twitter Acct     (Impressions last 30 days)       1,414

SMM Global Facebook Page  (Reach last-30 days)               6,462

SMM Linkedin Page                 (contacts)                              472

SMM Youtube Channel            (followers)                                 6 

SMM Instagram Page  *          (followers)                                0

Direct Email     *                                                          249,000

Total                                                                           257,354

Note*  Our Instagram acct was recently hacked so we had to start over again.

We have also cleansed our email database of subscribers who haven’t opened for some time and or have errors or other delivery issues with their email.

Black Swan Connection Newsletter Signup

ABOUT US

 

This post has not been tagged.

Share |
Permalink | Comments (0)
 
Community Search
Sign In